Well-characterised class effect
GLP-1 class gastrointestinal adverse events
Nausea, diarrhoea, constipation, vomiting and abdominal pain are the most common adverse events reported with GLP-1 receptor agonists and dual / triple agonists. They tend to be mild-to-moderate, concentrated during titration, and improve over time, but are also the leading reason for treatment discontinuation in trials.
What is known
- GI events are the most frequent class adverse event in every pivotal trial.
- Severity correlates with titration speed; slower titration consistently lowers discontinuation.
- Most GI events are mild-to-moderate; severe events (severe vomiting, dehydration) are uncommon but not rare.
What remains uncertain
- Severity prediction at the individual level — there is no validated pre-treatment test for personal GI tolerability.
- Optimal management of refractory GI events while preserving efficacy.
- Long-term GI motility effects and the contribution to severe gastroparesis-like presentations under post-marketing review.
Trial limitations
- Symptom reporting in trials may under-capture severity and chronicity compared with real-world cohorts.
- Discontinuation due to GI events varies across trial populations and titration schedules.
FAQs
- How long do GI side effects last?
- In most published trials, GI events are concentrated in the titration phase and decline over the following weeks. Individual experience varies; this site does not provide individualised tolerability advice.
- Should I stop the medicine if I have nausea?
- We do not provide individual treatment advice. Persistent or severe symptoms should be discussed with the prescriber who is managing the licensed treatment.
- Population-level signals do not establish individual-level risk for any specific patient.
- Pivotal trial detection limits mean rare events may be under-characterised.
- Association in observational data does not establish causation.
- This page is not a substitute for qualified clinical assessment or MHRA Yellow Card reporting.
Related UK regulatory topics
Related trials
Related mechanisms
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Regulatory document (MHRA/EMA/FDA)MHRA Yellow Card Scheme
UK pharmacovigilance reporting and signal detection
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — EPARs
EPARs include the signal-relevant SmPC sections
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of safety signals on this site